Adaptimmune Therapeutics PLC: Adaptimmune Reports First Quarter Financial Results and Business Update

Completed submission of the clinical module (Part 2) of the afami-cel BLA; afami-cel is targeted to be the first marketed engineered T-cell therapy for a solid tumorAdaptimmune and GSK agreed terms for

Related Keywords

Pennsylvania , United States , Canada , Philadelphia , American , Dana Lynch , Adrian Rawcliffe , Julip Miller , Securities Exchange , American Society Of Cell , American Society Of Clinical Oncology , Corporate Affairs , Corporate Communications , Therapeutics Inc , Company Quarterly Report On Form , United Newsfile Corp , Nasdaq , Cm Merger Sub Inc , Company Investor Relations Department At Copies , Parent Investor Relations Department , Exchange Commission , American Association For Cancer Research , Genentech , Chief Executive Officer , Regenerative Medicine Advanced Therapy , Cell Therapy Product Engineering , American Society , Gene Therapy , Annual Meeting , Afamitresgene Autoleucel , Sarcoma Track Poster Session , Clinical Oncology , American Association , Cancer Research , Adaptimmune General Meeting , March Press , Strategic Collaboration , License Agreement , Transfer Agreement , Quarterly Report , Specific Peptide Enhanced Affinity Receptor , Adaptimmune Therapeutics , Securities Act , Securities Exchange Act , American Depositary Shares , Annual Reports , Quarterly Reports , Registration Statement , Investor Relations Department , General Meeting , Annual Report , Total Liquidity , Consolidated Statement , Senior Director , Gefallene Big Techs , Adaptimmune , Herapeutics , Reports , First , Quarter , Financial , Results , Business , Update ,